NerPharMa S.r.l. announced new Board of Directors and Statutory Auditors
May 28, 2024

NERVIANO, 28, May 2024_NerPharMa, a veteran CDMO with a specialization in oncology small molecule drug manufacture and a member of NMS Group S.p.A, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company itself and of all its subsidiaries due to termination of mandates. This transition is part of our ongoing commitment to strong corporate governance and effective leadership.

NerPharMa Srl

Changes to the Board of Directors

We would like to inform you of the following appointments to our Board of Directors:

  • Hugues Dolgos (Chairman and CEO)
  • Claudio Salvagnini
  • Tiziano Lazzaretti

These appointments follow the conclusion of the mandates of the following directors:

  • Hugues Dolgos (Sole Director)

Changes to Statutory Auditors

Additionally, we are pleased to announce the appointment of new statutory auditors:

  • Andrea Piermartini Rosi (Sole Auditors)

These appointments follow the conclusion of the mandates of the following auditors:

  • Mario Tagliaferri (Chairman)
  • Giovanni Ghelfi
  • Stefano Sacchi

 

We extend our sincere gratitude to the outgoing directors and auditors for their dedicated service and valuable contributions to NMS Group and its subsidiaries. We welcome the new members and are confident that their expertise will significantly benefit the company.

 

Link PR: 20240528-NPM SRL new BoD and Statutory Auditors

Read more:  about the Board of Directors and Statutory Auditors of all NMS Group companies please click the link below:
https://www.nmsgroup.it/governance-and-ethics-compliance/

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO